首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   535437篇
  免费   32651篇
  国内免费   1500篇
耳鼻咽喉   6749篇
儿科学   16395篇
妇产科学   14710篇
基础医学   75503篇
口腔科学   11922篇
临床医学   48505篇
内科学   105560篇
皮肤病学   9622篇
神经病学   45037篇
特种医学   21968篇
外国民族医学   56篇
外科学   84264篇
综合类   10486篇
现状与发展   2篇
一般理论   344篇
预防医学   36816篇
眼科学   12400篇
药学   36962篇
  29篇
中国医学   1157篇
肿瘤学   31101篇
  2022年   3292篇
  2021年   7827篇
  2020年   4618篇
  2019年   7594篇
  2018年   10263篇
  2017年   7421篇
  2016年   8426篇
  2015年   9787篇
  2014年   13503篇
  2013年   19149篇
  2012年   26681篇
  2011年   27395篇
  2010年   16555篇
  2009年   15123篇
  2008年   24513篇
  2007年   26134篇
  2006年   25484篇
  2005年   24944篇
  2004年   23661篇
  2003年   21746篇
  2002年   20735篇
  2001年   15271篇
  2000年   15183篇
  1999年   13485篇
  1998年   5849篇
  1997年   5027篇
  1996年   4557篇
  1995年   4291篇
  1994年   3862篇
  1993年   3695篇
  1992年   9299篇
  1991年   9419篇
  1990年   9066篇
  1989年   8836篇
  1988年   7996篇
  1987年   7696篇
  1986年   7359篇
  1985年   7198篇
  1984年   5675篇
  1983年   4898篇
  1982年   3491篇
  1981年   3009篇
  1979年   4889篇
  1978年   3733篇
  1977年   3174篇
  1975年   3154篇
  1974年   3665篇
  1973年   3627篇
  1972年   3300篇
  1971年   3110篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
European Surgery - Large skin defects caused by trauma (e.g., burns) or due to other reasons (e.g., tumor-related skin resections) require sufficient skin replacement. The constant improvement of...  相似文献   
2.
Die Anaesthesiologie - Phantomschmerzen haben eine hohe Prävalenz nach Majoramputationen und sind mit einer zusätzlichen Einschränkung der Lebensqualität verbunden....  相似文献   
3.
4.
5.
6.
7.
8.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
9.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号